Close Menu

clinical trial

NEW YORK (GenomeWeb News) – Med Fusion today said that it has inked a validation and market development pact with Theranostics Health aimed at validating the clinical utility of Theranostics Health's personalized medicine assays.

NEW YORK (GenomeWeb News) – Curetis and Cempra today announced a collaboration for the use of Curetis' Unyvero molecular diagnostic system in Cempra's phase III trial for its oral drug for community-acquired bacterial pneumonia.

Idaho Technology said this week that it has initiated a clinical trial to evaluate its FilmArray Blood Culture Identification, or BCID, panel, which is designed to identify more than two dozen sepsis-causing organisms, as well as detect the presence of certain antibiotic resistan

NEW YORK (GenomeWeb News) – Mount Sinai Services in Toronto and Brigham and Women's Hospital in Boston are collaborating to test Axela's Risk of Recurrence Assay, the company said today.

Germany's Curetis has initiated a prospective clinical trial in the European Union for its Unyvero molecular testing system and P50 Pneumonia test cartridge, the company said in February.

Originally published Jan. 24. This article has been updated to include comments from Crescendo Bioscience's Ted Snelgrove, who spoke at a personalized medicine conference this week in Mt. View, Calif.

By Tony Fong
NEW YORK (GenomeWeb News) – Molecular diagnostics firm T2 Biosystems is set to begin a clinical trial for its first assay targeting Candida fungal infections as it prepares to seek regulatory approval in the US next year.

Pages

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.